Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Potential Efficacy, Safety and Tolerability of Different Oral Doses of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2021
Price :
$35
*
At a glance
- Drugs Ramosetron (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 19 Nov 2005 New trial record.